SEP 23, 2016 09:00 AM PDT

Access key technologies to accelerate genetic testing in your laboratory

SPONSORED BY: Natera, Natera
Speakers
  • Field Application Scientist Natera, Inc.
    Biography
      Samuel Suk received an M.S. in bioengineering from UCSD in La Jolla, California. Subsequently, he has held scientific support positions at Thermo Fisher and Fluidigm working with customers from a wide variety of industries. Currently, Samuel is a Field Application Scientist with Natera providing technical assistance worldwide to labs that are pursuing Panorama NIPT implementation.

    Abstract:
    DATE: September 23, 2016
    TIME:   9:00 AM PST, 12:00 PM ET

     
    As genetic testing becomes more pervasive, many clinical and pathology laboratories see next generation sequencing (NGS) as an attractive evolution of their lab’s testing capabilities. There is already precedent for reimbursement by private and public insurers for genetic testing, particularly NGS genetic testing. However the decision to choose a genetic test that has a large market potential, is reimbursable (or willingly paid for out-of-pocket), and is easy to implement is daunting. One such test that meets all three business needs is the non-invasive prenatal test (NIPT). NIPT is applicable to a very large market (ca. 136.8M births per year globally). It is reimbursed by more private or government insurance and is readily paid for by consumers directly. The test is now easily implemented in most laboratories through Natera’s technology licensing program. Natera has invested 10s of millions of dollars in research and development and makes these technologies available to licensees under its technology licensing program. By licensing from Natera, laboratories can access some of the same technologies employed for Natera’s Panorama NIPT. This includes key Natera reagents, bioinformatics algorithms, and scientific resources used to develop a powerful NIPT offering. This webinar will introduce Natera’s technology licensing program and explain the process in which prospective licensee labs may license key Natera technology to perform NIPT in their own labs thereby offering a market leading NIPT in their own market.

    *Only available in certain geographies. Talk with your local representative for availability in your country*

     

    Show Resources
    You May Also Like
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    AUG 16, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 16, 2018 08:00 AM PDT
    DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...
    APR 25, 2018 07:00 AM PDT
    C.E. CREDITS
    APR 25, 2018 07:00 AM PDT
    DATE: April 25, 2018TIME: 1500 CET, 10:00 a.m. EST, 7:00 a.m. PST Hematology and coagulation laboratories perform a wide range of routine and specialized tests, allowing clinicians to...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...